146 results
8-K
EX-99.1
PBLA
Panbela Therapeutics, Inc.
22 Apr 24
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
8:02am
, the prognosis for patients with mPDAC remains poor, with median overall survival still less than 12 months.
The incremental benefits in median survival have … outcomes for patients with mPDAC, beyond the incremental benefits observed with the recently approved therapy," added Dr. Simpson. "The early
POS AM
u3nlhmdr
29 Mar 24
Prospectus update (post-effective amendment)
5:08pm
8-K
EX-10.1
12g4dfzotbse759
13 Feb 24
Departure of Directors or Certain Officers
5:24pm
8-K
EX-4.4
0l0b9ndj38rg0
29 Jan 24
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
6:21am
8-K
EX-4.3
zi6uk2u ugrqy98k
29 Jan 24
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
6:21am
8-K
EX-10.2
0dmu8e65
29 Jan 24
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
6:21am
8-K
EX-10.1
w9xul
29 Jan 24
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
6:21am